Vercise, which is based on cochlear implant technology, is designed to stimulate a targeted region of the brain via independently controlled leads.
The 292-patient Intrepid trial of subjects with advanced, levodopa-responsive Parkinson’s is a double-blind, sham-controlled study with a primary endpoint of improvement in on time at 12 weeks and a secondary outcome of change in Unified Parkinson’s Disease Rating Scale and quality-of-life assessments, also at 12 weeks.
The one-year results, released at the annual conference of the American Academy of Neurology in Los Angeles, showed a six-hour improvement in on time free of dyskinesia and a 49.2% improvement in UPDRS scores measuring motor symptoms. Quality-of-life scores, measured using the Parkinson’s Disease Questionnaire 39, showed an overall sustained improvement; Boston Scientific said more than 40% of the Vercise programming delivered current over two or more contacts.
“This study meets a new level of rigor in evaluating the effectiveness of a DBS system,” coordinating principal investigator Dr. Jerrold Vitek, of the University of Minnesota Medical School, said in prepared remarks. “The double-blind design gives us confidence that the improvements in patients on time with good symptom control, as evaluated by the diary data, are an objective measure of the outcomes and suggests patients will benefit from the Vercise System.”
These featured panels at DeviceTalks Boston will explore the state of R&D at major medtech firms, as well as the latest trends when it comes to developing combination products, neuromodulation devices, robotic systems and women's health technology.
View Technology Track Featured Sessions
Register today to save. Use code TECHTRACK to save an additional 10%.